1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain
| Autor: | Garcia Campelo, M.R., Domine Gomez, M., De Castro Carpeno, J., Moreno Vega, A.L., Ponce Aix, S., Arriola, E., Carcereny Costa, E., Majem Tarruella, M., Huidobro Vence, G., Esteban Gonzalez, E., Fuentes Pradera, J., Ortega Granados, A.L.O., Guillot Morales, M., Massuti Sureda, B., Vila Martinez, L., Blasco Cordellat, A., Fajardo, C.A., Crama, L., Lerones Laborda, N., Cobo Dols, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1246-S1247 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|